{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Rhabdomyosarcomas&page=10", "query": { "condition": "Rhabdomyosarcomas", "page": 10 }, "page_size": 10 }, "pagination": { "page": 10, "page_size": 10, "total_count": 282, "total_pages": 29, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Rhabdomyosarcomas&page=11&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Rhabdomyosarcomas&page=9&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T16:25:52.912Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02581384", "title": "Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Ewing Sarcoma", "Rhabdomyosarcoma", "Wilms Tumor", "Osteosarcoma", "Non-Rhabdomyosarcoma Soft Tissue Sarcoma, Nos", "Renal Tumor", "Rhabdoid Tumor", "Clear Cell Renal Cell Carcinoma", "Sarcoma", "Sarcoma, Ewing", "Soft Tissue Sarcoma" ], "interventions": [ { "name": "Stereotactic Body Radiotherapy (SBRT)", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 5, "start_date": "2017-01", "completion_date": "2020-08", "has_results": true, "last_update_posted_date": "2021-04-30", "last_synced_at": "2026-10-14T16:25:52.912Z", "location_count": 3, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02581384" }, { "nct_id": "NCT06521567", "title": "A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Melanoma", "Hodgkin Lymphoma", "High and Low Grade Glioma", "Glioblastoma Multiforme (GBM)", "Diffuse Intrinsic Pontine Glioma (DIPG)", "Ependymoma", "Osteosarcoma", "Hepatic Tumors", "Hepatoblastoma", "Hepatocellular Carcinoma (HCC)", "Fibrolamellar Carcinoma", "Rhabdomyosarcoma" ], "interventions": [ { "name": "Cobolimab", "type": "DRUG" }, { "name": "Dostarlimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "0 Years to 21 Years" }, "enrollment_count": 83, "start_date": "2025-03-06", "completion_date": "2026-10-13", "has_results": false, "last_update_posted_date": "2025-11-12", "last_synced_at": "2026-10-14T16:25:52.912Z", "location_count": 6, "location_summary": "Los Angeles, California • Iowa City, Iowa • Hackensack, New Jersey + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT06521567" }, { "nct_id": "NCT00007813", "title": "Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain and Central Nervous System Tumors", "Childhood Germ Cell Tumor", "Extragonadal Germ Cell Tumor", "Liver Cancer", "Neuroblastoma", "Ovarian Cancer", "Sarcoma", "Testicular Germ Cell Tumor" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "autologous bone marrow transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "35 Years", "sex": "ALL", "summary": "Up to 35 Years" }, "enrollment_count": 21, "start_date": "1997-05-31", "completion_date": "2005-02-01", "has_results": false, "last_update_posted_date": "2020-02-17", "last_synced_at": "2026-10-14T16:25:52.912Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00007813" }, { "nct_id": "NCT01742286", "title": "Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "ALK-activated Tumors" ], "interventions": [ { "name": "Ceritinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "17 Years", "sex": "ALL", "summary": "12 Months to 17 Years" }, "enrollment_count": 83, "start_date": "2013-08-28", "completion_date": "2019-04-26", "has_results": true, "last_update_posted_date": "2020-06-09", "last_synced_at": "2026-10-14T16:25:52.912Z", "location_count": 5, "location_summary": "Boston, Massachusetts • New York, New York • Cincinnati, Ohio + 2 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Memphis", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01742286" }, { "nct_id": "NCT04284774", "title": "Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Malignant Solid Neoplasm", "Recurrent Adrenal Gland Pheochromocytoma", "Recurrent Ectomesenchymoma", "Recurrent Ependymoma", "Recurrent Ewing Sarcoma", "Recurrent Hepatoblastoma", "Recurrent Kidney Wilms Tumor", "Recurrent Langerhans Cell Histiocytosis", "Recurrent Malignant Germ Cell Tumor", "Recurrent Malignant Glioma", "Recurrent Medulloblastoma", "Recurrent Melanoma", "Recurrent Neuroblastoma", "Recurrent Non-Hodgkin Lymphoma", "Recurrent Osteosarcoma", "Recurrent Peripheral Primitive Neuroectodermal Tumor", "Recurrent Rhabdoid Tumor", "Recurrent Rhabdoid Tumor of the Kidney", "Recurrent Rhabdomyosarcoma", "Recurrent Soft Tissue Sarcoma", "Recurrent Thyroid Gland Carcinoma", "Recurrent WHO Grade 2 Glioma", "Refractory Adrenal Gland Pheochromocytoma", "Refractory Ependymoma", "Refractory Ewing Sarcoma", "Refractory Hepatoblastoma", "Refractory Langerhans Cell Histiocytosis", "Refractory Malignant Germ Cell Tumor", "Refractory Malignant Glioma", "Refractory Medulloblastoma", "Refractory Melanoma", "Refractory Neuroblastoma", "Refractory Non-Hodgkin Lymphoma", "Refractory Osteosarcoma", "Refractory Peripheral Primitive Neuroectodermal Tumor", "Refractory Rhabdoid Tumor", "Refractory Rhabdoid Tumor of the Kidney", "Refractory Rhabdomyosarcoma", "Refractory Soft Tissue Sarcoma", "Refractory Thyroid Gland Carcinoma", "Refractory WHO Grade 2 Glioma" ], "interventions": [ { "name": "Tipifarnib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "21 Years", "sex": "ALL", "summary": "12 Months to 21 Years" }, "enrollment_count": 5, "start_date": "2020-10-13", "completion_date": "2027-09-30", "has_results": true, "last_update_posted_date": "2026-07-15", "last_synced_at": "2026-10-14T16:25:52.912Z", "location_count": 171, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 129 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT04284774" }, { "nct_id": "NCT04337177", "title": "Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors", "Neuroblastoma", "Rhabdomyosarcoma", "Ewing Sarcoma", "Hepatoblastoma", "Medulloblastoma" ], "interventions": [ { "name": "VAL-413", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Valent Technologies, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "30 Years", "sex": "ALL", "summary": "1 Year to 30 Years" }, "enrollment_count": 20, "start_date": "2021-10-25", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-07-30", "last_synced_at": "2026-10-14T16:25:52.912Z", "location_count": 11, "location_summary": "Phoenix, Arizona • San Francisco, California • Washington D.C., District of Columbia + 8 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT04337177" }, { "nct_id": "NCT00623077", "title": "MT2004-30: Tomotherapy for Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain and Central Nervous System Tumors", "Kidney Cancer", "Liver Cancer", "Retinoblastoma", "Sarcoma" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "busulfan", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "ifosfamide", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "thiotepa", "type": "DRUG" }, { "name": "stem cell transplantation", "type": "PROCEDURE" }, { "name": "tomotherapy", "type": "RADIATION" }, { "name": "total marrow irradiation", "type": "RADIATION" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Whole lung radiation", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "70 Years", "sex": "ALL", "summary": "Up to 70 Years" }, "enrollment_count": 23, "start_date": "2005-08", "completion_date": "2016-10", "has_results": false, "last_update_posted_date": "2017-12-05", "last_synced_at": "2026-10-14T16:25:52.912Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00623077" }, { "nct_id": "NCT04901702", "title": "Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Recurrent Solid Tumor", "Recurrent Ewing Sarcoma", "Recurrent Hepatoblastoma", "Recurrent Malignant Germ Cell Tumor", "Recurrent Malignant Solid Neoplasm", "Recurrent Neuroblastoma", "Recurrent Osteosarcoma", "Recurrent Peripheral Primitive Neuroectodermal Tumor", "Recurrent Rhabdoid Tumor", "Recurrent Rhabdomyosarcoma", "Recurrent Soft Tissue Sarcoma", "Recurrent Wilms Tumor", "Refractory Ewing Sarcoma", "Refractory Hepatoblastoma", "Refractory Malignant Germ Cell Tumor", "Refractory Malignant Solid Neoplasm", "Refractory Neuroblastoma", "Refractory Osteosarcoma", "Refractory Peripheral Primitive Neuroectodermal Tumor", "Refractory Rhabdoid Tumor", "Refractory Rhabdomyosarcoma", "Refractory Soft Tissue Sarcoma" ], "interventions": [ { "name": "Onivyde", "type": "DRUG" }, { "name": "Talazoparib", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "30 Years", "sex": "ALL", "summary": "12 Months to 30 Years" }, "enrollment_count": 90, "start_date": "2021-06-09", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-05-19", "last_synced_at": "2026-10-14T16:25:52.912Z", "location_count": 7, "location_summary": "Palo Alto, California • Aurora, Colorado • Washington D.C., District of Columbia + 4 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04901702" }, { "nct_id": "NCT03655587", "title": "Impact of an Orthotic Intervention in Children With Peripheral Neuropathy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Gait, Drop Foot", "Chemotherapy-induced Peripheral Neuropathy", "Acute Lymphocytic Leukemia, Pediatric", "Rhabdomyosarcoma", "Wilms Tumor" ], "interventions": [ { "name": "Solid ankle foot orthotic", "type": "DEVICE" }, { "name": "Resting night splint", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Children's Hospitals and Clinics of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": "14 Years", "sex": "ALL", "summary": "5 Years to 14 Years" }, "enrollment_count": 27, "start_date": "2016-09-20", "completion_date": "2022-05-18", "has_results": false, "last_update_posted_date": "2023-02-10", "last_synced_at": "2026-10-14T16:25:52.912Z", "location_count": 2, "location_summary": "Minneapolis, Minnesota • Memphis, Tennessee", "locations": [ { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03655587" }, { "nct_id": "NCT00025363", "title": "Comparison of Chemotherapy Regimens in Treating Children With Relapsed or Progressive Rhabdomyosarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Alveolar Childhood Rhabdomyosarcoma", "Embryonal Childhood Rhabdomyosarcoma", "Embryonal-botryoid Childhood Rhabdomyosarcoma", "Previously Treated Childhood Rhabdomyosarcoma", "Recurrent Childhood Rhabdomyosarcoma" ], "interventions": [ { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "irinotecan hydrochloride", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "ifosfamide", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "tirapazamine", "type": "DRUG" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "pharmacogenomic studies", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "20 Years", "sex": "ALL", "summary": "Up to 20 Years" }, "enrollment_count": 150, "start_date": "2001-11", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-17", "last_synced_at": "2026-10-14T16:25:52.912Z", "location_count": 1, "location_summary": "Arcadia, California", "locations": [ { "city": "Arcadia", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00025363" } ] }